US 12,257,287 B2
Glucagon-derived peptide and use thereof
Yingmei Han, Tianjin (CN); Wei Liu, Tianjin (CN); Bingni Liu, Tianjin (CN); Weiling Kong, Tianjin (CN); Naxia Zhao, Tianjin (CN); Guangping Xia, Tianjin (CN); Qian Shang, Tianjin (CN); Xiaohua Kong, Tianjin (CN); Jing Jin, Tianjin (CN); Yuquan Li, Tianjin (CN); and Xuyuan Liu, Tianjin (CN)
Assigned to Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin (CN)
Appl. No. 17/292,922
Filed by Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin (CN)
PCT Filed Nov. 12, 2019, PCT No. PCT/CN2019/117715
§ 371(c)(1), (2) Date May 11, 2021,
PCT Pub. No. WO2020/103729, PCT Pub. Date May 28, 2020.
Claims priority of application No. 201811338218.2 (CN), filed on Nov. 12, 2018.
Prior Publication US 2024/0252592 A1, Aug. 1, 2024
Int. Cl. A61K 38/26 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01)
CPC A61K 38/26 (2013.01) [A61P 3/04 (2018.01); A61P 3/10 (2018.01)] 20 Claims
 
1. A polypeptide derivative, modified derivative or salt thereof, comprising a polypeptide having a sequence of general formula Ia:
 
 (SEQ ID NO: 38)
 
 HX2QGTFTSDX10SKYLEX16X17X18
 
 
 
 AX20EFX23X24WLX27X28X29X30
 
 General Formula Ia
wherein,
X2 is Ser or Aib;
X10 is Tyr or Lys;
X16 is Ser or Glu;
X17 is Arg, Glu or Lys;
X18 is Lys, Ala or Arg;
X20 is Arg or Lys;
X23 is Val or Ile;
X24 is Ala, Glu or Lys;
X27 is Leu or absent;
X28 is Glu or absent;
X29 is Ala;
X30 is Z, and Z is a fragment peptide GGPSSG (SEQ ID NO:37);
one of X10, X17, X20 or X24 is Lys with a modified side chain; and
C-terminal carboxyl group is free or amidated.